Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trialRandall J. Bateman, Bruno Dubois, Tammie L.S. Benzinger et al.|The Lancet Neurology|2025Cited by 39
α‐Synuclein seed amplification assay detects Lewy body co‐pathology in autosomal dominant Alzheimer's disease late in the disease course and dependent on Lewy pathology burdenJohannes Levin, James M. Noble, Matthew P. Frosch et al.|Alzheimer s & Dementia|2024Cited by 37
Comparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer's disease: a cross-sectional studyJulie K. Wisch, Beau M. Ances, Adam M. Brickman et al.|The Lancet Neurology|2024Cited by 35